Medicine and Dentistry
Burkitt's Lymphoma
100%
Disease
64%
Overall Survival
53%
B-Cell Chronic Lymphocytic Leukemia
50%
Diagnosis
50%
Progression Free Survival
49%
Central Nervous System
43%
Allogeneic Hematopoietic Stem Cell Transplantation
43%
Cancer
37%
Transplantation
36%
Prognostication
30%
T Cell
30%
Human Immunodeficiency Virus
29%
B Cell
27%
Cell Therapy
25%
MALT Lymphoma
25%
Hematopoietic Stem Cell
25%
Autologous Stem Cell Transplantation
25%
Viral Respiratory Tract Infection
25%
Leukemia Survival
25%
B Lymphocyte Receptor
25%
Chemotherapy Regimens
25%
Cohort Analysis
25%
Virus Infection
25%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
25%
Myeloablative Conditioning
25%
Geriatric Assessment
25%
Gut Microbiome
25%
Infectious Complication
25%
Myeloid Malignancy
25%
Multiplex Polymerase Chain Reaction
25%
Malignant Neoplasm
25%
Hematologic Malignancy
25%
Decitabine
25%
Systematic Review
25%
B-Cell Lymphoma
24%
Hematopoietic Stem Cell Transplantation
22%
Drug Megadose
18%
Chimeric Antigen Receptor T-Cell Therapy
16%
Immune Reconstitution
16%
Infection
15%
Immunosuppressive Treatment
15%
Prognostic Factor
14%
Cyclophosphamide
13%
Immunophenotyping
12%
Immune Deficiency
12%
Oncologist
12%
Blood Brain Barrier
12%
Survival Rate
12%
Brain Biopsy
12%
Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
75%
Lymphoma
41%
Overall Survival
30%
Burkitt Lymphoma
27%
Community-acquired Respiratory Viruses
25%
Decitabine
25%
Myeloablative Conditioning
25%
R-CHOP
25%
Immune Reconstitution
25%
Chemotherapy Regimen
25%
Infectious Complications
25%
HIV-associated
25%
B-cell Malignancies
25%
Double-hit Lymphoma
25%
Myeloid Malignancies
25%
Collaborative Analysis
25%
NCCN Clinical Practice Guidelines
25%
Oncology
25%
Cell Therapy
25%
Clinical High Risk
25%
Burkitt
25%
Initial Treatment
25%
Light Chain Amyloidosis
25%
Shifting Roles
25%
Cancer Comorbidity
25%
HIV-related
18%
Progression-free Survival
17%
Complete Response
12%
Intensive Regimens
12%
Curative Intent
12%
Refractory Lymphoma
12%
Adoptive Cell Therapy
12%
Aggressive B-cell Lymphoma
12%
Mate-pair Sequencing
12%
Inflammatory Toxicity
12%
Stem Cell Transplantation
12%
Lymphoma Subtype
12%
Prognostic Factors
12%
Confidence Interval
12%
Efficacy-toxicity
12%
Risk Mitigation Measures
12%
CD19
12%
Revaccination
12%
High Dose
12%
CAR T-cell Therapy
12%
Central Nervous System Involvement
12%
United States
10%
Central Nervous System Recurrence
10%
Amyloid Fibrils
10%
Intensive Care Medicine
8%
Pharmacology, Toxicology and Pharmaceutical Science
Burkitt's Lymphoma
75%
Chronic Lymphatic Leukemia
50%
Progression Free Survival
46%
Overall Survival
44%
B Lymphocyte Receptor
30%
HIV
29%
Dimer
25%
Decitabine
25%
Cohort Study
25%
Infectious Complication
25%
Malignant Neoplasm
25%
Recurrent Disease
25%
Viral Respiratory Tract Infection
25%
Respiratory Virus
25%
Virus Infection
20%
Infection
13%
Cyclophosphamide
13%
Survival Rate
12%
Cyclophosphamide Plus Doxorubicin Plus Etoposide Plus Prednisolone Plus Rituximab Plus Vincristine
12%
Disease
9%
Ibrutinib
8%
Lower Respiratory Tract Infection
8%
Neoplasm
6%
Intrathecal
6%
Human Immunodeficiency Virus Infection
6%
Central Nervous System Disease
6%
Graft Versus Host Reaction
5%
Cytarabine
5%
Doxorubicin
5%
Etoposide
5%
Methotrexate
5%
Ifosfamide
5%
Vincristine
5%